RU2007109601A - Антагонисты vla-4 - Google Patents
Антагонисты vla-4 Download PDFInfo
- Publication number
- RU2007109601A RU2007109601A RU2007109601/04A RU2007109601A RU2007109601A RU 2007109601 A RU2007109601 A RU 2007109601A RU 2007109601/04 A RU2007109601/04 A RU 2007109601/04A RU 2007109601 A RU2007109601 A RU 2007109601A RU 2007109601 A RU2007109601 A RU 2007109601A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- hydrogen
- independently selected
- aryl
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Claims (12)
1. Соединение формулы I:
или его фармацевтически приемлемая соль,
где A представляет собой N или N+-О-;
X и Y независимо выбраны из галогена, C1-3алкила и С1-3алкокси;
R1 выбран из (1) водорода, (2) C1-10алкила, (3) -(C1-10алкил)арила, (4) -(C1-10алкил)-O-C1-10алкила, (5) -(C1-10алкил)-OC(О)-C1-10алкила, (6) -(C1-10алкил)-OC(О)-арила, (7) -(C1-10алкил)-OC(O)O- C1-10алкила и (8) -(C1-10алкил)-N+(C1-3алкил)3; где алкил необязательно замещен 1-3 заместителями, независимо выбранными из Ra, и арил необязательно замещен 1-3 заместителями, независимо выбранными из Rb;
R2 представляет собой водород или метил;
один из R3 и R4 представляет собой водород и другой представляет собой
k равно 0 до 4;
R5 и R6 независимо выбраны из водорода, фтора, CF3 и CO2Rf, при условии, что
R5 и R6, оба, не являются водородом;
R7 и R8 независимо выбраны из H, -SO2-C1-3алкила, CN, CF3, OCF3 и галогена;
Ra выбран из (1) -ORd, (2) -NRdS(O)mRe, (3) -NO2, (4) галогена, (5) -S(O)mRd, (6) -SRd, (7) -S(O)2ORd, (8) -S(O)mNRdRe, (9) -NRdRe, (10) -O(CRfRg)nNRdRe, (11) -C(O)Rd, (12) -CO2Rd, (13) -CO2(CRfRg)nCONRdRe, (14) -OC(O)Rd, (15) -CN, (16) -C(O)NRdRe, (17) -NRdC(O)Re, (18) -OC(O)NRdRe, (19) -NRdC(O)ORe, (20) -NRdC(O)NRdRe, (21) -CRd(N-ORe), (22) CF3, (23) -OCF3, (24) C3-8циклоалкила и (25) гетероциклила; где циклоалкил и гетероциклил необязательно замещены 1-3 группами, независимо выбранными из Rc;
Rb выбран из (1) группы, выбранной из Ra, (2) C1-10алкила, (3) C2-10алкенила (4) C2-10алкинила, (5) арила и (6) -(C1-10алкил)арила, где алкил, алкенил, алкинил и арил необязательно замещены одним-тремя заместителями, выбранными из группы, независимо выбранной из Rc;
Rc представляет собой (1) галоген, (2) амино, (3) карбокси, (4) C1-4алкил, (5) C1-4алкокси, (6) арил, (7) -(C1-4алкил)арил, (8) гидрокси, (9) CF3, (10) OC(O)C1-4алкил, (11) OC(O)NRfRg или (12) арилокси;
Rd и Re независимо выбраны из водорода, C1-10алкила, C2-10-алкенила, C2-10алкинила, Cy и -(C1-10алкил)-Cy, где алкил, алкенил, алкинил и Cy независимо замещены одним-четырьмя заместителями, независимо выбранными из Rc; или
Rd и Re вместе с атомом(ами), с которым они связаны, образуют гетероциклическое кольцо с от 4 до 7 членами, содержащее 0-2 дополнительных гетероатомов, независимо выбранных из O, S и N-Rh;
Rf и Rs независимо выбраны из водорода, С1-10алкила, Cy и -(C1-10алкил)-Cy; или
Rf и Rg вместе с углеродом, с которым они связаны, образуют кольцо с от 5 до 7 членами, содержащее 0-2 гетероатома, независимо выбранные из кислорода, серы и азота;
Rh выбран из Rf и -C(O)Rf;
Cy выбран из циклоалкила, гетероциклила, арила и гетероарила;
m равно 1 или 2; и
n равно 2 до 5.
2. Соединение по п.1, где один из X и Y представляет собой галоген и другой выбран из галогена, С1-3алкила и С1-3алкокси.
3. Соединение по п.1, где R1 представляет собой водород, С1-4алкил, -(С1-4алкил)ОС1-4алкил или -(С1-4алкил)N+(C1-3алкил)3.
6. Соединение по п.1, имеющее формулу Ia:
или его фармацевтически приемлемая соль,
где A представляет собой N или N+O-;
R1 выбран из водорода, C1-10алкила, -(С1-4алкил)арила, -(С1-4алкил)-О-С1-4алкила и -(С1-4алкил)-N+(C1-3алкил)3;
один из R3 и R4 представляет собой водород и другой выбран из
где один из R5 и R6 представляет собой F и другой представляет собой H или F, k равно 0 до 4, и k' равно 0 до 2;
R7 и R8 независимо выбраны из H, SO2-C1-3алкила, CN, CF3, OCF3, и галогена.
7. Соединение по п.6, где k равно 0 до 2.
8. Соединение по п.6, где R3 представляет собой водород и R4 выбран из 3,3-дифтор-1-азетидинила, 3,3-дифтор-1-пирролидинила и 3,3-дифтор-1-пиперидинила.
9. Соединение по п.7, где R7 представляет собой 3-циано и R8 представляет собой водород.
10. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
11. Применение соединения по п.1 или его фармацевтически приемлемой соли для получения лекарственного средства для лечения или профилактики заболеваний, опосредованных клеточной адгезией.
12. Применение по п.9, где указанное заболевание выбрано из астмы, рассеянного склероза, воспалительной болезни кишечника, хронической обструктивной болезни легких, серповидно-клеточной (дрепаноцитарная) анемии, лейкоза и ревматоидного артрита.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60194204P | 2004-08-16 | 2004-08-16 | |
US60/601,942 | 2004-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007109601A true RU2007109601A (ru) | 2008-09-27 |
Family
ID=35502447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007109601/04A RU2007109601A (ru) | 2004-08-16 | 2005-08-12 | Антагонисты vla-4 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7776891B2 (ru) |
EP (1) | EP1781686B1 (ru) |
JP (1) | JP4649476B2 (ru) |
KR (1) | KR20070044054A (ru) |
CN (1) | CN101006097B (ru) |
AT (1) | ATE430761T1 (ru) |
AU (1) | AU2005277634B2 (ru) |
BR (1) | BRPI0514415A (ru) |
CA (1) | CA2576647C (ru) |
DE (1) | DE602005014364D1 (ru) |
IL (1) | IL181267A0 (ru) |
MX (1) | MX2007001876A (ru) |
NO (1) | NO20071399L (ru) |
RU (1) | RU2007109601A (ru) |
WO (1) | WO2006023396A2 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1874299A2 (en) * | 2005-04-21 | 2008-01-09 | Merck & Co., Inc. | Vla-4 antagonists |
WO2008156721A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Diphenyl substituted alkanes |
WO2017173302A2 (en) * | 2016-04-01 | 2017-10-05 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CR20210213A (es) | 2018-10-30 | 2021-06-24 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de la integrina alfa4beta7 |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
US6338084B1 (en) * | 1998-12-17 | 2002-01-08 | International Business Machines Corporation | Method for process-specific exchange of data between machines in a network |
RU2245874C2 (ru) | 1999-02-18 | 2005-02-10 | Ф.Хоффман-Ля Рош Аг | Производные тиоамида и фармацевтическая композиция |
MXPA01013406A (es) * | 1999-06-30 | 2003-09-04 | Daiichi Seiyaku Co | Compuestos inhibidores de vla-4. |
DE60033684T2 (de) | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
PT1244625E (pt) * | 1999-12-06 | 2005-09-30 | Hoffmann La Roche | 4-piridinil-n-acil-l-fenilalaninas |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
JP3824935B2 (ja) * | 1999-12-06 | 2006-09-20 | エフ.ホフマン−ラ ロシュ アーゲー | 4−ピリミジニル−n−アシル−l−フェニルアラニン |
JP2004526733A (ja) | 2001-03-20 | 2004-09-02 | メルク エンド カムパニー インコーポレーテッド | 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体 |
US6855708B2 (en) | 2001-03-20 | 2005-02-15 | Merck & Co., Inc. | N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors |
US6559174B2 (en) | 2001-03-20 | 2003-05-06 | Merck & Co., Inc. | N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
CA2558893A1 (en) | 2004-03-10 | 2005-09-22 | Merck & Co., Inc. | Vla-4 antagonists |
-
2005
- 2005-08-12 EP EP05808535A patent/EP1781686B1/en not_active Not-in-force
- 2005-08-12 JP JP2007527893A patent/JP4649476B2/ja not_active Expired - Fee Related
- 2005-08-12 US US11/659,608 patent/US7776891B2/en active Active
- 2005-08-12 CN CN2005800277189A patent/CN101006097B/zh not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514415-9A patent/BRPI0514415A/pt not_active Application Discontinuation
- 2005-08-12 AU AU2005277634A patent/AU2005277634B2/en not_active Ceased
- 2005-08-12 WO PCT/US2005/028768 patent/WO2006023396A2/en active Application Filing
- 2005-08-12 CA CA2576647A patent/CA2576647C/en not_active Expired - Fee Related
- 2005-08-12 DE DE602005014364T patent/DE602005014364D1/de active Active
- 2005-08-12 MX MX2007001876A patent/MX2007001876A/es unknown
- 2005-08-12 AT AT05808535T patent/ATE430761T1/de not_active IP Right Cessation
- 2005-08-12 RU RU2007109601/04A patent/RU2007109601A/ru not_active Application Discontinuation
- 2005-08-12 KR KR1020077006034A patent/KR20070044054A/ko not_active Application Discontinuation
-
2007
- 2007-02-11 IL IL181267A patent/IL181267A0/en unknown
- 2007-03-15 NO NO20071399A patent/NO20071399L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP1781686A2 (en) | 2007-05-09 |
US7776891B2 (en) | 2010-08-17 |
WO2006023396A3 (en) | 2006-04-27 |
CA2576647A1 (en) | 2006-03-02 |
WO2006023396A2 (en) | 2006-03-02 |
JP4649476B2 (ja) | 2011-03-09 |
NO20071399L (no) | 2007-05-08 |
MX2007001876A (es) | 2007-05-09 |
BRPI0514415A (pt) | 2008-06-10 |
KR20070044054A (ko) | 2007-04-26 |
IL181267A0 (en) | 2007-07-04 |
CN101006097A (zh) | 2007-07-25 |
US20070219252A1 (en) | 2007-09-20 |
EP1781686B1 (en) | 2009-05-06 |
JP2008510005A (ja) | 2008-04-03 |
CN101006097B (zh) | 2012-07-11 |
AU2005277634A1 (en) | 2006-03-02 |
AU2005277634B2 (en) | 2011-02-17 |
ATE430761T1 (de) | 2009-05-15 |
CA2576647C (en) | 2011-12-13 |
DE602005014364D1 (de) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007109601A (ru) | Антагонисты vla-4 | |
US9949951B2 (en) | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | |
KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
JP6279605B2 (ja) | 自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ(RORγ)のモジュレーター | |
JP5891235B2 (ja) | C型肝炎ウイルスの新規阻害剤 | |
RU2015107738A (ru) | Ингибиторы hcv ns3 протеазы | |
JP2012528166A5 (ru) | ||
RU2007127849A (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов | |
PE20091307A1 (es) | Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica | |
JP2013510178A5 (ru) | ||
JP2005505618A5 (ru) | ||
JP6380777B2 (ja) | PI3K、mTOR阻害薬としての縮合キノリン化合物 | |
KR20060027802A (ko) | 3환계 화합물 | |
JP2016535769A5 (ru) | ||
WO2010000030A1 (en) | Thiazopyrimidinones and uses thereof | |
WO2016207212A1 (en) | Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway | |
MX2012008147A (es) | Derivados de pirrazolopiridina. | |
KR20130141554A (ko) | 신규한 항암제 | |
AU2005245561B2 (en) | Substituted pyrrole-2, 5-diones as protein kinase C inhibitors | |
JPWO2018016458A1 (ja) | ピペラジン誘導体 | |
WO2022007168A1 (zh) | 一种苯并五元氮杂环化合物及其应用 | |
JP2005533038A5 (ru) | ||
Saku et al. | Synthetic study of VLA-4/VCAM-1 inhibitors: Synthesis and structure–activity relationship of piperazinylphenylalanine derivatives | |
KR20120113886A (ko) | 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물 및 그를 함유한 약제학적 조성물 | |
ES2559295T3 (es) | Un compuesto para el tratamiento de la hepatitis C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080922 |
|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080922 |
|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080922 |